Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.37 |
| ▸ | HTR3A | P46098 | 2/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008831 | 0.97 | MAP3K7 (0.38) | HRH3CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6007791 | 0.96 | HRH3 (0.41) | HRH3CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6008794 | 0.96 | HRH3 (0.39) | HRH3CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6007555 | 0.95 | HRH3 (0.43) | HRH3CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6006117 | 0.94 | CHRNA7 (0.35) | HRH3CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6008732 | 0.94 | HPGD (0.35) | HRH3CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6007827 | 0.94 | CHRNA7 (0.35) | HRH3CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6008486 | 0.90 | CHRNA7 (0.38) | CHRNA7HTR3ACHRNB2CHRNA4 | |
| SCHEMBL6008809 | 0.90 | CHRNA7 (0.38) | CHRNA7HTR3ACHRNB2CHRNA4MAPT | |
| SCHEMBL6007740 | 0.89 | CHRNA7 (0.37) | CHRNA7HTR3ACHRNB2CHRNA4MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | claimed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | claimed |
| US-7067515-B2 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045540-A1 | Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease | NQO2, SLC10A1, CYP7A1 | HRH3 471/4885CHRNA7 594/4885HTR3A 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.